Rofecoxib (Vioxx)--the first of a new generation of NSAIDs.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed medicines in practice and, although of undoubted benefit for many, they are potentially toxic for some. Does rofecoxib, and the others which will inevitably follow, hold out the promise of safe and effective NSAID therapy in the future?
MacConnachie
A M
AM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy / Q000451:nursing; D017281:Cost of Illness; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D011307:Drug Prescriptions; D004363:Drug Utilization; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000191:economics / Q000453:epidemiology; D006801:Humans; D007783:Lactones / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib